ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients
- PMID: 35486908
- PMCID: PMC9257990
- DOI: 10.1002/cac2.12296
ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients
Conflict of interest statement
The authors declare no conflict of interest, except that Liu has equity interest in Bluewater Biotech LLC.
Figures

Similar articles
-
Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.Oncotarget. 2016 May 24;7(21):30119-32. doi: 10.18632/oncotarget.8798. Oncotarget. 2016. PMID: 27121061 Free PMC article.
-
Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells.Med Sci Monit. 2017 Jun 1;23:2674-2683. doi: 10.12659/msm.904810. Med Sci Monit. 2017. PMID: 28570501 Free PMC article.
-
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.Oncogene. 2012 Apr 26;31(17):2222-36. doi: 10.1038/onc.2011.393. Epub 2011 Sep 26. Oncogene. 2012. PMID: 21996729
-
Estrogen Actions in Triple-Negative Breast Cancer.Cells. 2020 Oct 26;9(11):2358. doi: 10.3390/cells9112358. Cells. 2020. PMID: 33114740 Free PMC article. Review.
-
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic.Endocrinology. 2022 Jan 1;163(1):bqab235. doi: 10.1210/endocr/bqab235. Endocrinology. 2022. PMID: 34791151 Review.
Cited by
-
Establishment of a prognostic model toward lung squamous cell carcinoma based on m7G-related genes in the cancer genome atlas.Physiol Genomics. 2023 Oct 1;55(10):427-439. doi: 10.1152/physiolgenomics.00149.2022. Epub 2023 Aug 14. Physiol Genomics. 2023. PMID: 37575065 Free PMC article.
-
Identification of TUBB2A as a Cancer-Immunity Cycle-Related Therapeutic Target in Triple-Negative Breast Cancer.Mol Biotechnol. 2024 Sep;66(9):2467-2480. doi: 10.1007/s12033-023-00880-2. Epub 2023 Sep 24. Mol Biotechnol. 2024. PMID: 37742297
-
Prognostic evaluation of pancreatic cancer based on the model of chemo-radiotherapy resistance-related genes.J Gastrointest Oncol. 2023 Jun 30;14(3):1525-1545. doi: 10.21037/jgo-23-308. Epub 2023 Jun 19. J Gastrointest Oncol. 2023. PMID: 37435207 Free PMC article.
References
-
- Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019;199:30–57. - PubMed
-
- Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, et al. Genome and transcriptome sequencing in prospective metastatic triple‐negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013;12(1):104–16. - PubMed
-
- Desmedt C, Haibe‐Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–65. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical